FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Junia Melo

Research Profile

Disorders

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Genes, abl

Anatomy

Procedures

Polymerase Chain Reaction

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Peter Valent; Stefan Wöhrer; Johannes Zuber; Michael Andreeff; Michel AROCK; Dominique Bonnet; Sabine Cerny-Reiterer; Christine Chomienne; Mhairi Copland; Ruggero De Maria; Harald Herrmann; Brian Huntly; Fumihiko Ishikawa; Hans E Johnsen; Tsvee Lapidot; Junia V Melo; Alexander Roesch; Jan Jacob Schuringa; Gerrit Jan Schuurhuis; Jean Soulier; Giorgio Stassi; Connie Eaves
Cancer stem cell definitions and terminology: the devil is in the details.
Swagata Roy; Gordon Strathdee; Mohamed Abed El Baky; Tessa L Holyoake; Heather G Jørgensen; Junia V Melo; Poornima Roy; Chris Bartholomew
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Beate Schultheis; H Yin; Roger G Gosden; Bart A Nijmeijer; Junia V Melo
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Junia Melo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Peter Valent; Stefan Wöhrer; Johannes Zuber; Michael Andreeff; Michel AROCK; Dominique Bonnet; Sabine Cerny-Reiterer; Christine Chomienne; Mhairi Copland; Ruggero De Maria; Harald Herrmann; Brian Huntly; Fumihiko Ishikawa; Hans E Johnsen; Tsvee Lapidot; Junia V Melo; Alexander Roesch; Jan Jacob Schuringa; Gerrit Jan Schuurhuis; Jean Soulier; Giorgio Stassi; Connie Eaves
Cancer stem cell definitions and terminology: the devil is in the details.
Nature reviews. Cancer 2012;12(11):767-75.
2012: Swagata Roy; Gordon Strathdee; Mohamed Abed El Baky; Tessa L Holyoake; Heather G Jørgensen; Junia V Melo; Poornima Roy; Chris Bartholomew
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
British journal of haematology 2012;157(4):446-56.
2012: Beate Schultheis; H Yin; Roger G Gosden; Bart A Nijmeijer; Junia V Melo
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.
Leukemia research 2012;36(3):271-4.
2012: Daniel B Lipka; Junia V Melo; Carsten Müller-Tidow; Mirle Schemionek; Tina Schnöder; Marie-Christine Wagner; Marek Dziadosz; Florian Heidel; Thomas Kindler; Steffen Koschmieder; Thomas Fischer
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
PloS one 2012;7(7):e40853.
2011: Ruriko Tanaka; Hisashi Wakita; Hisayuki Yao; Mariko Yoshimura; Eishi Ashihara; Yoshihiro Hayashi; Hideyo Hirai; Kuniaki Itoh; Shinya Kimura; Junia V Melo; Rina Nagao; Kaichi Nishiwaki; Oliver G Ottmann; Sakiko Satake; Ken-Ichi Sawada; Kenshi Suzuki; Naoto Takahashi; Taira Maekawa
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Cancer letters 2011;312(2):228-34.
2011: Angelo M Carella; John M Goldman; Giovanni Martinelli; Junia V Melo; Danilo Perrotti
Chronic myeloid leukemia: the basis of treatment for tomorrow.
Haematologica 2011;96(12):1737-9.
2011: Nicola Esposito; Timothy P Hughes; Thea Kalebic; Luigia Luciano; Giovanni Martinelli; Rosanna Martinelli; Junia V Melo; Anna Lucia Peluso; Marco Picardi; Concetta Quintarelli; Jerald P Radich; Margherita Ruoppolo; Domenico Russo; Giuseppe Saglio; Agostino Rodeo Sica; Deborah White; Susan Branford; Tonia Buonomo; Irene Colavita; Luigi Del Vecchio; Fabrizio Pane
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Blood 2011;118(13):3634-44.
2011: Carolyn M Butcher; Catherine L Carmichael; Peter G Bardy; Lena Eriksson; ID Lewis; Junia V Melo; Petra J Neufing; Hamish S Scott; Ella J Wilkins; Richard J D'Andrea
RUNX1 mutations are rare in chronic phase polycythaemia vera.
British journal of haematology 2011;153(5):672-5.
2011: Joana M Diamond; Junia V Melo
Mechanisms of resistance to BCR-ABL kinase inhibitors.
Leukemia & lymphoma 2011;52 Suppl 1():12-22.
2010: Junia V Melo; Duncan R Hewett
Wrapping BCR-ABL: it's in the bag.
Blood 2010;116(18):3382-3.
2010: Joannah Score; María J Calasanz; O Ottman; F Pane; R F Yeh; M A Sobrinho-Simões; Sebastian Kreil; D Ward; C Hidalgo-Curtis; Junia V Melo; J Wiemels; B Nadel; Nicholas C P Cross; Francis H Grand
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.
Leukemia 2010;24(10):1742-50.
2010: Irene Colavita; Nicola Esposito; Rosanna Martinelli; Francesca Catanzano; Junia V Melo; Fabrizio Pane; Margherita Ruoppolo; Francesco Salvatore
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Biochimica et biophysica acta 2010;1804(10):1974-87.
2010: Manuel Sobrinho-Simões; Vicki Wilczek; Joannah Score; Nicholas C P Cross; Jane F Apperley; Junia V Melo
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Blood 2010;116(8):1329-35.
2010: Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi A Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood 2010;115(21):4206-16.
2010: Shannon McWeeney; Lucy C Pemberton; Marc Loriaux; Kristina Vartanian; Stephanie G Willis; Gregory Yochum; Beth Wilmot; Yaron Turpaz; Raji Pillai; Brian J Druker; Jennifer L Snead; Mary MacPartlin; Stephen G O'Brien; Junia V Melo; Thoralf Lange; Christina A Harrington; Michael W N Deininger
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
Blood 2010;115(2):315-25.
2009: Susan Branford; Junia V Melo; Timothy P Hughes
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Blood 2009;114(27):5426-35.
2009: Jost Klawitter; Douglas J Kominsky; Jaimi L Brown; Jost Klawitter; Uwe Christians; Dieter Leibfritz; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
British journal of pharmacology 2009;158(2):588-600.
2009: Agnes S M Yong; Junia V Melo
The impact of gene profiling in chronic myeloid leukaemia.
Best practice & research. Clinical haematology 2009;22(2):181-90.
2009: Douglas J Kominsky; Jelena Klawitter; Jaimi L Brown; Laszlo G Boros; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3442-50.
2009: Ana Batlle; Vasiliki Papadopoulou; Ana R Gomes; Shaun Willimott; Junia V Melo; Kikkeri Naresh; Eric W-F Lam; Simon D Wagner
CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression.
Molecular immunology 2009;46(8-9):1727-35.
2009: Lisa J Crawford; Phlip Windrum; Laura Magill; Junia V Melo; Lynn McCallum; Mary Frances McMullin; Huib Ovaa; Brian Walker; Alexandra E Irvine
Proteasome proteolytic profile is linked to Bcr-Abl expression.
Experimental hematology 2009;37(3):357-66.
2009: Andrew Chase; Beate Schultheis; Sebastian Kreil; J Baxter; C Hidalgo-Curtis; A Jones; L Zhang; Francis H Grand; Junia V Melo; Nicholas C P Cross
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.
Leukemia 2009;23(2):358-64.
2009: Charles Chuah; Junia V Melo
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.
OncoTargets and therapy 2009;2():83-94.
2008: Mohamad Mohty; Richard Szydlo; Agnes S M Yong; Jane F Apperley; John M Goldman; Junia V Melo
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
Blood 2008;112(5):2163-6.
2008: Selina Raguz; Rebecca A Randle; Eva R Sharpe; John A Foekens; Anieta M Sieuwerts; Marion E Meijer-Van Gelder; Junia V Melo; Christopher F Higgins; Ernesto Yagüe
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
International journal of cancer. Journal international du cancer 2008;122(5):1058-67.
2008: John M Goldman; Junia V Melo
BCR-ABL in chronic myelogenous leukemia--how does it work?
Acta haematologica 2008;119(4):212-7.
2007: D Brazma; Colin Grace; J Howard; Junia V Melo; T Holyoke; J F Apperley; Elisabeth P Nacheva
Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.
Genes, chromosomes & cancer 2007;46(11):1039-50.
2007: Gordon Strathdee; Tessa L Holyoake; Alyson Sim; Anton Parker; David Oscier; Junia V Melo; Stefan Meyer; Tim O B Eden; Anne M Dickinson; joanne mountford; Heather G Jørgensen; Richard Soutar; Robert Brown
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5048-55.
2007: Mohamad Mohty; Agnes S M Yong; Richard Szydlo; Jane F Apperley; Junia V Melo
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.
Blood 2007;110(1):380-3.
2007: Stephen D Griffiths; John Burthem; Richard D Unwin; Tessa L Holyoake; Junia V Melo; Guy S Lucas; Anthony D Whetton
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.
Molecular biotechnology 2007;36(2):81-9.
2007: Heiko Konig; Nicolai Härtel; Beate Schultheis; Michael Schatz; Christian Lorentz; Junia V Melo; Rüdiger Hehlmann; Andreas Hochhaus; Paul La Rosée
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica 2007;92(6):838-41.
2007: Junia V Melo; David J Barnes
Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Nature reviews. Cancer 2007;7(6):441-53.
2007: Junia V Melo; Charles Chuah
Resistance to imatinib mesylate in chronic myeloid leukaemia.
Cancer letters 2007;249(2):121-32.
2007: Gigi M O Møller; Victoria Frost; Junia V Melo; Andrew Chantry
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
FEBS letters 2007;581(7):1329-34.
2007: David J Barnes; S De; P van Hensbergen; E Moravcsik; Junia V Melo
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Leukemia 2007;21(3):421-6.
2007: Enrica I Lerma; Viet-Anh Nguyen; Tao Wang; Alex J Tipping; Junia V Melo; Donald Kufe; David J Austin; Albert Deisseroth
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
Molecular cancer therapeutics 2007;6(2):655-66.
2007: Chikashi Yoshida; Fumiko Yoshida; Daniel E Sears; Stephen M Hart; Dai Ikebe; Akihiko Muto; Subham Basu; Kazuhiko Igarashi; Junia V Melo
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.
Blood 2007;109(3):1211-9.
2007: M Pocaly; Valérie Lagarde; Gabriel Etienne; J-A Ribeil; Stéphane Claverol; Marc Bonneu; François Moreau-Gaudry; V Guyonnet-Duperat; O Hermine; Junia V Melo; Maryse Dupouy; B Turcq; François-Xavier Mahon; Jean-Max Pasquet
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
Leukemia 2007;21(1):93-101.
2007: Atsushi Ono; Kazuteru Kono; Dai Ikebe; Akihiko Muto; Jiying Sun; Masao Kobayashi; Kazuhiro Ueda; Junia V Melo; Kazuhiko Igarashi; Satoshi Tashiro
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Genes, chromosomes & cancer 2007;46(1):67-74.
2006: David J Barnes; Junia V Melo
Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia.
Cell cycle (Georgetown, Tex.) 2006;5(24):2862-6.
2006: Paul La Rosée; Taiping Jia; Shadmehr Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W N Deininger
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6540-6.
2006: Thomas Pabst; Erica Stillner; Donna Neuberg; Stephen D Nimer; Cheryl L Willman; Alan F List; Junia V Melo; Daniel G Tenen; Beatrice U Mueller
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.
British journal of haematology 2006;133(4):400-2.
2006: Ling Yan Zhang; Matthew L Smith; Beate Schultheis; Jude Fitzgibbon; T Andrew Lister; Junia V Melo; Nicholas C P Cross; Jamie Cavenagh
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Leukemia research 2006;30(4):373-8.
2006: Agnes S M Yong; Richard Szydlo; John M Goldman; Jane F Apperley; Junia V Melo
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Blood 2006;107(1):205-12.
2005: C Chuah; David J Barnes; M Kwok; Amie S Corbin; Michael W N Deininger; Brian J Druker; Junia V Melo
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Leukemia 2005;19(11):1896-904.
2005: David J Barnes; Danai Palaiologou; Eleni Panousopoulou; Beate Schultheis; Agnes S M Yong; Alice Wong; Laura Pattacini; John M Goldman; Junia V Melo
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Cancer research 2005;65(19):8912-9.
2005: David J Barnes; Beate Schultheis; Simisade Adedeji; Junia V Melo
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Oncogene 2005;24(42):6432-40.
2005: A Radujkovic; Moritz Schad; Julian Topaly; Marlon R Veldwijk; Stephanie Laufs; B S Schultheis; Anna Jauch; Junia V Melo; Stefan Fruehauf; W Jens Zeller
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Leukemia 2005;19(7):1198-206.
2005: Beate Schultheis; Richard Szydlo; François-Xavier Mahon; Jane F Apperley; Junia V Melo
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.
Blood 2005;105(12):4893-4.
2005: Víctor Javier Sánchez-Arévalo Lobo; Clara Isabel Aceves Luquero; Luis Alvarez-Vallina; Alex J Tipping; Juan Guinea Viniegra; Javier Hernandez Losa; Carlos Parada Cobo; Eva María Galán Moya; Jorge Gayoso Cruz; Junia V Melo; Santiago Ramón y Cajal; Ricardo Sánchez-Prieto
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
The Biochemical journal 2005;387(Pt 1):231-8.
2005: Vanessa Desplat; Francis Belloc; Valérie Lagarde; Catherine Boyer; Junia V Melo; Josy Reiffers; Vincent Praloran; François-Xavier Mahon
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Cancer 2005;103(1):102-10.
2004: Alex J Tipping; S Baluch; David J Barnes; Darren R Veach; B M Clarkson; William G Bornmann; François-Xavier Mahon; John M Goldman; Junia V Melo
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Leukemia 2004;18(8):1352-6.
2004: Kate Cwynarski; Ruthline Laylor; E Macchiarulo; J Goldman; Giovanna Lombardi; Junia V Melo; Francesco Dazzi
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.
Leukemia 2004;18(8):1332-9.
2004: Junia V Melo; Michael W N Deininger
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Hematology/oncology clinics of North America 2004;18(3):545-68, vii-viii.
2004: Chikashi Yoshida; Junia V Melo
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
International journal of hematology 2004;79(5):420-33.
2004: Alex J Tipping; Junia V Melo
Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells.
Leukemia research 2004;28(3):219-20.
2004: Paul La Rosée; Kara Johnson; Amie S Corbin; Eric P Stoffregen; Erika M Moseson; Stephanie Willis; Michael J Mauro; Junia V Melo; Michael W N Deininger; Brian J Druker
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Blood 2004;103(1):208-15.
2003: Alex J Tipping; Michael W N Deininger; John M Goldman; Junia V Melo
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Experimental hematology 2003;31(11):1073-80.
2003: John M Goldman; Junia V Melo
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
The New England journal of medicine 2003;349(15):1451-64.
2003: Chi Ly; Adrian F Arechiga; Junia V Melo; Craig M Walsh; S Tiong Ong
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Cancer research 2003;63(18):5716-22.
2003: Julian Topaly; Moritz Schad; Stephanie Laufs; Junia V Melo; W Jens Zeller; Stefan Fruehauf
Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
British journal of haematology 2003;121(4):672-3.
2003: Rong Dong; Kate Cwynarski; Alan Entwistle; Federica M Marelli-Berg; Francesco Dazzi; Elizabeth Simpson; John M Goldman; Junia V Melo; Robert I Lechler; Ilaria Bellantuono; Anne Ridley; Giovanna Lombardi
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Blood 2003;101(9):3560-7.
2003: Alex J Tipping; Junia V Melo
Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies.
Seminars in hematology 2003;40(2 Suppl 2):83-91.
2003: François-Xavier Mahon; Francis Belloc; Valérie Lagarde; Claudine Chollet; François Moreau-Gaudry; Josy Reiffers; John M Goldman; Junia V Melo
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Blood 2003;101(6):2368-73.
2003: Persis J Amrolia; Steven D Reid; Liquan Gao; Beate Schultheis; Gianpietro Dotti; Malcolm K Brenner; Junia V Melo; John M Goldman; Hans J Stauss
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Blood 2003;101(3):1007-14.
2003: Junia V Melo; Timothy P Hughes; Jane F Apperley
Chronic myeloid leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():132-52.
2003: David J Barnes; Junia V Melo
Management of chronic myeloid leukemia: targets for molecular therapy.
Seminars in hematology 2003;40(1):34-49.
2002: John M L Ebos; Jennifer Tran; Zubin Master; Daniel J Dumont; Junia V Melo; Elisabeth Buchdunger; Robert S Kerbel
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Molecular cancer research : MCR 2002;1(2):89-95.
2002: Alex J Tipping; François-Xavier Mahon; GEORGE ZAFIRIDES; Valérie Lagarde; John M Goldman; Junia V Melo
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Leukemia 2002;16(12):2349-57.
2002: Christophe Barthe; Marie-Josée Gharbi; Valérie Lagarde; Claudine Chollet; Pascale Cony-Makhoul; Josy Reiffers; John M Goldman; Junia V Melo; François-Xavier Mahon
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
British journal of haematology 2002;119(1):109-11.
2002: Lucio Luzzatto; Francesco Frassoni; Junia V Melo
Imatinib: can one outwit chronic myeloid leukemia?
Haematologica 2002;87(9):898-901.
2002: Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-Xavier Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
The New England journal of medicine 2002;347(7):481-7.
2002: Lucio Luzzatto; Junia V Melo
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.
Blood 2002;100(3):1105.
2002: Russell R Hoover; Francois-Xavier Mahon; Junia V Melo; George Q Daley
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Blood 2002;100(3):1068-71.
2002: R Tabrizi; François-Xavier Mahon; Pascale Cony-Makhoul; Valérie Lagarde; Francis Lacombe; Patrice Berthaud; Junia V Melo; Josy Reiffers; Francis Belloc
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
Leukemia 2002;16(6):1154-9.
2002: Stephen G O'Brien; Sara A D Vieira; Samantha Connors; Nick Bown; James Chang; Renaud Capdeville; Junia V Melo
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Blood 2002;99(9):3465-7.
2002: Beate Schultheis; Melina Carapeti-Marootian; Andreas Hochhaus; Andreas Weisser; John M Goldman; Junia V Melo
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Blood 2002;99(5):1766-75.
2002: Delphine Sauce; Marie Bodinier; Marina I Garin; Bruno Petracca; Nicolas Tonnelier; Anne Duperrier; Junia V Melo; Jane F Apperley; Christophe Ferrand; Patrick Hervé; François Lang; Pierre Tiberghien; Eric Robinet
Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.
Blood 2002;99(4):1165-73.
2002: David J Barnes; Junia V Melo
Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia.
Acta haematologica 2002;108(4):180-202.
2001: Alex J Tipping; François-Xavier Mahon; Valérie Lagarde; John M Goldman; Junia V Melo
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.
Blood 2001;98(13):3864-7.
2001: A Demiroglu; E J Steer; C Heath; Kerry Taylor; Mark Bentley; Steven Allen; Prasad R K Koduru; JP Brody; G Hawson; Robyn Rodwell; M L Doody; F Carnicero; A Reiter; John M Goldman; Junia V Melo; Nicholas C P Cross
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Blood 2001;98(13):3778-83.
2001: S A Vieira; Michael W N Deininger; A Sorour; Paul Sinclair; Letizia Foroni; John M Goldman; Junia V Melo
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
Genes, chromosomes & cancer 2001;32(4):353-63.
2001: Michael W N Deininger; S A Vieira; Y Parada; Lolita Banerji; Eric W-F Lam; G Peters; François-Xavier Mahon; T Köhler; John M Goldman; Junia V Melo
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Cancer research 2001;61(21):8005-13.
2001: Christophe Barthe; Pascale Cony-Makhoul; Junia V Melo; J R Mahon
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2001: Junia V Melo; A Kumberova; A G van Dijk; John M Goldman; M R Yuille
Investigation on the role of the ATM gene in chronic myeloid leukaemia.
Leukemia 2001;15(9):1448-50.
2001: D Chalmers; Christophe Ferrand; Jane F Apperley; Junia V Melo; Saskia B Ebeling; I Newton; Anne Duperrier; Anton Hagenbeek; E Garrett; Pierre Tiberghien; Marina I Garin
Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(2):146-8.
2001: Marina I Garin; E Garrett; Pierre Tiberghien; Jane F Apperley; D Chalmers; Junia V Melo; Christophe Ferrand
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.
Blood 2001;97(1):122-9.
2000: François-Xavier Mahon; Michael W N Deininger; Beate Schultheis; J Chabrol; J Reiffers; John M Goldman; Junia V Melo
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 2000;96(3):1070-9.
2000: Michael W N Deininger; S Vieira; R Mendiola; Beate Schultheis; John M Goldman; Junia V Melo
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer research 2000;60(7):2049-55.
2000: Marina I Garin; Jane F Apperley; Junia V Melo
Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood.
European journal of haematology 2000;64(2):85-92.
1999: E Garrett; Marina I Garin; A R Miller; John M Goldman; Junia V Melo; Jane F Apperley
Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296.
British journal of haematology 1999;107(2):401-8.
1998: J Gora-Tybor; Michael W N Deininger; John M Goldman; Junia V Melo
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
British journal of haematology 1998;103(3):716-20.
1998: S Bose; Michael W N Deininger; J Gora-Tybor; John M Goldman; Junia V Melo
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Blood 1998;92(9):3362-7.
1998: Michael W N Deininger; S Bose; J Gora-Tybor; X H Yan; John M Goldman; Junia V Melo
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.
Cancer research 1998;58(3):421-5.
1997: Michael W N Deininger; John M Goldman; N Lydon; Junia V Melo
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood 1997;90(9):3691-8.
1997: A Hochhaus; X H Yan; A Willer; R Hehlmann; Myrtle Y Gordon; John M Goldman; Junia V Melo
Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia.
Leukemia 1997;11(7):933-9.
1997: Junia V Melo
BCR-ABL gene variants.
Baillière's clinical haematology 1997;10(2):203-22.
1996: Andreas Hochhaus; A Reiter; Heyko Skladny; Junia V Melo; C Sick; Ute Berger; J Q Guo; R B Arlinghaus; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: A Spencer; X H Yan; Andrew Chase; John M Goldman; Junia V Melo
BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions.
British journal of haematology 1996;94(4):654-8.
1996: Junia V Melo; X H Yan; J Diamond; F Lin; Nicholas C P Cross; John M Goldman
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.
Leukemia 1996;10(7):1217-21.
1996: F Al-Jehani; Andreas Hochhaus; A Spencer; John M Goldman; Junia V Melo
Expression of the LH2 gene in chronic myeloid leukaemia cells.
Leukemia 1996;10(7):1122-6.
1996: F van Rhee; Andreas Hochhaus; F Lin; Junia V Melo; John M Goldman; Nicholas C P Cross
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood 1996;87(12):5213-7.
1996: Junia V Melo
The molecular biology of chronic myeloid leukaemia.
Leukemia 1996;10(5):751-6.
1996: Junia V Melo; Andreas Hochhaus; X H Yan; John M Goldman
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
British journal of haematology 1996;92(3):684-6.
1995: Junia V Melo; John M Goldman
Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743).
Leukemia 1995;9(8):1407-8.
1995: J Diamond; John M Goldman; Junia V Melo
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Blood 1995;85(8):2171-5.
1995: Junia V Melo; X H Yan; J Diamond; John M Goldman
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Leukemia 1995;9(4):734-9.
1994: Junia V Melo; N S Kent; X H Yan; John M Goldman
Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.
Blood 1994;84(11):3984-6.
1994: Junia V Melo; X H Yan; J Diamond; John M Goldman
Lack of imprinting of the ABL gene.
Nature genetics 1994;8(4):318-9.
1994: S G O'Brien; M A Kirkland; Junia V Melo; M H Rao; R J Davidson; C McDonald; John M Goldman
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Leukemia 1994;8(12):2156-62.
1994: Junia V Melo; Han Myint; D A Galton; John M Goldman
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Leukemia 1994;8(1):208-11.
1994: Nicholas C P Cross; Junia V Melo; L Feng; John M Goldman
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
Leukemia 1994;8(1):186-9.
1993: Junia V Melo; D E Gordon; A Tuszynski; S Dhut; Bryan D Young; John M Goldman
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Blood 1993;81(10):2488-91.
1993: Junia V Melo; D E Gordon; Nicholas C P Cross; John M Goldman
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
Blood 1993;81(1):158-65.
1992: Junia V Melo; John M Goldman
Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Leukemia 1992;6(8):786-90.
1988: Junia V Melo; L Foroni; V Brito-Babapulle; Lucio Luzzatto; D Catovsky
The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.
Clinical and experimental immunology 1988;73(1):23-8.
1987: Junia V Melo; D S Robinson; C Gregory; D Catovsky
Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia.
Leukemia 1987;1(4):294-8.
1987: V Brito-Babapulle; S Pittman; Junia V Melo; M Pomfret; D Catovsky
Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia.
Hematologic pathology 1987;1(1):27-33.
1986: Junia V Melo; V Brito-Babapulle; L Foroni; D S Robinson; Lucio Luzzatto; D Catovsky
Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement.
International journal of cancer. Journal international du cancer 1986;38(4):531-8.
1986: V Brito-Babapulle; S Pittman; Junia V Melo; L Parreira; D Catovsky
The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases.
Leukemia research 1986;10(2):131-8.
1985: Junia V Melo; L Foroni; V Brito Babapulle; D S Lewis; M Bennett; D Robinson; L Parreira; Lucio Luzzatto; D Catovsky
Prolymphocytic leukemia of B cell type: rearranged immunoglobulin (Ig) genes with defective Ig production.
Blood 1985;66(2):391-8.
1984: V Brito-Babapulle; Junia V Melo; L Foroni; D Robinson; L Parreira; M Brozovic; D Catovsky
Neoplastic kappa and lambda cells in a B-PLL with chromosome translocations of both light chain gene regions.
International journal of cancer. Journal international du cancer 1984;34(6):769-73.
1984: D Catovsky; M O'Brien; Junia V Melo; J Wardle; M Brozovic
Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia.
Seminars in oncology 1984;11(4):362-9.